A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

NCT04228783 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

974

Enrollment

INDUSTRY

Sponsor class

Conditions

Ebola

Interventions

BIOLOGICAL: Ad26.ZEBOV
BIOLOGICAL: MVA-BN-Filo
BIOLOGICAL: Placebo

Sponsor

Janssen Vaccines & Prevention B.V.